Advertisement
Home Tags Immunotherapy

Tag: Immunotherapy

Guideline Issued for Management of Inhalant Allergies With Immunotherapy

Authors strongly recommend that clinician performing allergy skin testing or allergen immunotherapy be able to diagnose, manage anaphylaxis

Pembrolizumab Improves Event-Free Survival in Early NSCLC

For resectable early-stage NSCLC, improved event-free survival seen with pembrolizumab, regardless of N status, clinical stage, type of surgery

Secondary Primary Malignancies Rare After CAR T-Cell Immunotherapy

Projected five-year incidence of 15.2 and 2.3 percent for solid and hematologic malignancies after CAR T-cell immunotherapy

Cancer Vaccine Safe, Induces T-Cell Responses for KRAS-Mutated Tumors

Lymph node-targeting Amphiphile vaccine is safe; correlation seen for efficacy with T-cell response

End-of-Life Treatment With Immunotherapy Increasing for Patients With Cancer

Those treated at nonacademic or low-volume facilities have higher odds of initiating therapy within one month of death

MSI-H Colorectal Cancer Rarely Recurs After Immunotherapy Cessation

88 percent of 64 patients remained without disease progression after median of 22.6 months after stopping immunotherapy

ASH: Ibrutinib-Venetoclax Beneficial for Relapsed/Refractory Lymphoma

Improvement seen in progression-free survival for patients with relapsed/refractory mantle cell lymphoma

ASH: Daratumumab Beneficial for Patients With Multiple Myeloma

Addition of daratumumab to VRd results in improved progression-free survival for transplantation-eligible patients

Study Looks at Survival in Metastatic NSCLC Treated With Immunotherapy

Survival similar among racial and ethnic groups; ECOG performance status linked to survival

ASH: MRD-Directed Ibrutinib-Venetoclax Treatment Beneficial in Leukemia

Improvement in survival seen with measurable residual disease-directed ibrutinib-venetoclax versus fludarabine-cyclophosphamide-rituximab